Literature DB >> 2444548

Observations with Bazoton in the management of prostatic hyperplasia.

I Romics1.   

Abstract

Thirty patients with prostatic hyperplasia stages I and II were administered Bazoton capsules (extract of Radix Urticae) for an average period of 3.5 months. Residual urine, mean and maximal flow were measured before and after treatment. A significant decrease in the volume of residual urine was found. Increase in mean urinary flow was also significant. Maximal urinary flow increased in 50% of the cases. A marked subjective relief was reported by the patients. Bazoton is regarded as suitable for the conservative treatment of prostatic hyperplasia stages I and II.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444548     DOI: 10.1007/bf02549866

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  7 in total

1.  Reproducibility of uroflowmetry variables in elderly males.

Authors:  K M Jensen; J B Jørgensen; P Mogensen
Journal:  Urol Res       Date:  1985

2.  Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH).

Authors:  W Bartsch; H Becker; F A Pinkenburg; M Krieg
Journal:  Acta Endocrinol (Copenh)       Date:  1979-04

3.  [Fluorescence microscopic studies of prostate cells treated with Extract. radicis urticae].

Authors:  H Ziegler
Journal:  Fortschr Med       Date:  1983-12-01

4.  [Cytomorphologic studies of benign prostate hyperplasia treated with extract radicis urticae (ERU). Preliminary results].

Authors:  H Ziegler
Journal:  Fortschr Med       Date:  1982-10-21

Review 5.  The pathogenesis of benign prostatic hyperplasia.

Authors:  J D Wilson
Journal:  Am J Med       Date:  1980-05       Impact factor: 4.965

6.  [Effect of radix urticae extract and its several secondary extracts on blood SHBG in benign prostate hyperplasia].

Authors:  K Schmidt
Journal:  Fortschr Med       Date:  1983-04-21

7.  [Endocrinologic aspects of benign prostatic hyperplasia (prostatic adenoma). (Can hormone therapy of the disease be justified in 1984?)].

Authors:  I Holló; C Horváth
Journal:  Orv Hetil       Date:  1984-10-28       Impact factor: 0.540

  7 in total
  1 in total

1.  Experience with the Peponen capsule in the management of benign prostatic hyperplasia.

Authors:  A Hamvas; G Corradi; M Hegedüs; D Frang
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.